跳至主要内容
临床试验/NCT00525356
NCT00525356已完成3 期

INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection

Medtronic Bakken Research Center2 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2002年2月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
136
试验地点
2
主要终点
all-cause mortality

研究概览

简要总结

The objective of this study is to compare treatment with an endograft prothesis versus antihypertensive treatment in patients with a dissection of the thoracic aorta.

详细描述

Patients older than 18 years with type B aortic dissection as diagnosed by computed tomography or magnetic resonance angiography are randomized to either a thoracic aortic endoprosthesis and antihypertensive treatment, called "stent grafting," or a tailored antihypertensive treatment, called "medical treatment."

Only patients in a clinically stable condition and without spontaneous thrombosis of the false lumen after 14 days of the index dissection are considered eligible for study inclusion.

Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (>5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study design calls for 136 patients to be randomized and monitored for 24 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • No contraindication for an anesthetic procedure with intubation
  • Type B aortic dissection that occurred 2-52 weeks before randomization
  • Diameter of the targeted aortic segment ≤6 cm
  • Aortic kinking <75°
  • The subject or legal guardian understands the nature of the study and agrees to its provisions on a written informed consent form
  • Availability for the appropriate follow-up visits during the follow-up period
  • Capability to follow all study requirements

排除标准

  • Pregnant woman
  • Thrombocytopenia or ongoing anticoagulation therapy
  • Renal failure and/or creatinine >2.4 mg%
  • Complete thrombosis of the false lumen
  • Ongoing infection
  • Cancer is likely to cause death within 1 year
  • Enrolment in another clinical study
  • Unwillingness to cooperate with study procedures or follow-up visits

结局指标

主要结局

all-cause mortality

时间窗: 1 year

次要结局

  • thrombosis of the false lumen, cardiovascular morbidity, degree of aortic expansion, length of intensive care and hospital stay, and quantitative assessment of single or combination antihypertensive drug therapy.(5 years)

研究者

发起方
Medtronic Bakken Research Center
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验